Status:
UNKNOWN
Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)
Lead Sponsor:
Bernstein, Jonathan A., M.D.
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Rhinitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.
Detailed Description
Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at t...
Eligibility Criteria
Inclusion
- Aged 18 - 65 years
- Diagnosed with NARES
Exclusion
- Smokers, exposed to passive smoke
- Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or vasomotor rhinitis (VMR)
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00406094
Start Date
November 1 2006
End Date
December 1 2009
Last Update
January 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bernstein Allergy Group
Cincinnati, Ohio, United States, 45231